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and palmitoyl-CoA to murine t-ACBP using
heteronuclear NMR spectroscopy
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Introduction
The apoptosis-inducing potential of the sphingolipid cera-
mide is well known,1 yet the exact mechanism is still poorly
understood. In an attempt to identify proteins involved in
ceramide-induced apoptosis, we screened retrovirally-mutage-
nized Chinese hamster ovary (CHO) cells for cells resistant to
C2-ceramide-induced apoptosis.
2 One of the cell lines identified
contained an insertion into the promoter region of the gene
coding for the testis-specific isoform of acyl-CoA (t-ACBP)
(NM_021294; NP_067269; mouse protein O09035). Antibodies
were raised against recombinantly-produced protein, which
showed that in CHO cells t-ACBP localizes to the mitochondria,
which is consistent with what has been observed for other ACBP
proteins.3, 4 Whether the antibodies are specific for t-ACBP, as
opposed to other members of the family, has not been deter-
mined. We have shown subsequently that transduction of
recombinantly-produced t-ACBP protein into CHO cells leads
to apoptosis by activation of caspase 3 (M. Meyer et al., manu-
script in preparation).
t-ACBP is an 87-residue mouse protein belonging to the
acyl-CoA-binding protein family (ACBP), and sharing 54%
amino acid sequence identity with bovine liver acyl-CoA-
binding protein. ACBP proteins bind long-chain (C14–C22)
acyl-CoA esters with nanomolar affinity.5,6 The ACBP family can
be sub-divided into a number of groups on the basis of primary
sequence: l-ACBP, which is expressed in all tissue types and
appears to play a role in acyl-CoA metabolism; b-ACBP, which is
expressed predominantly in brain; t-ACBP, which is also known
as ‘endozepine’ or ‘endozepine-like peptide’, is expressed pre-
dominantly in testis and appears to play a role in spermato-
genesis;7–9 and m-ACBP, which forms part of larger proteins
which may be membrane associated. Although t-ACBP does not
appear to be expressed in primates,10 it is expressed in rat testis7–9
and in Chinese hamster ovary cells, where it is found predomi-
nantly in mitochondria.2 There is some confusion in the litera-
ture as to the use of the name ‘endozepine’: although in early
works it was used to refer to the whole class of ACBP/DBI pro-
teins,11–14 more recently it has come to be used to denote the tes-
tis-specific form of ACBP.7–10,15 However, there is also a wide
literature on ‘endogenous benzodiazepine-like compounds’
(see, for example, ref. 16), which are also called ‘endozepines’
and should not be confused with acyl-CoA binding proteins.
Acyl-CoA binding proteins were initially identified as
neuropeptides which inhibited binding of diazepam to the
benzodiazepine-binding site on the GABAA receptor,
14,17 giving
rise to the alternative name ‘diazepine binding inhibitors’ or
‘DBIs’.18,19 However, their ability to function as neuropeptides
remains to be verified.6 In the meantime, ACBPs have been
shown to play a role in a wide range of cellular functions, includ-
ing fatty chain elongation, protein sorting and vesicular traffick-
ing.20 ACBPs are included among a number of proteins released
from mitochondria following opening of the mitochondrial per-
meability transition pore complex (PTPC) during apoptosis.21,22
While the observed protein is described in ref. 21 as ‘endo-
zepine’, it is clear from the data that it is l-ACPB, rather than
t-ACBP, to which they are referring. Ligation of the mitochon-
drial (peripheral) benzodiazepine receptor (PBR), which is local-
ized in the mitochondrial membrane,23 has been shown to lead to
opening of the PTPC.24 Since ACBPs also bind to the PBR,25–27 it is
possible that ACBPs are involved in regulating the opening of
the PTPC during apoptosis. In that case, a possible explanation
for the enabling effect of t-ACBP on ceramide-induced apoptosis
is that ceramide directly modulates the interaction of t-ACBP
with the PBR, leading to opening of the PTPC.
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Murine t-ACBP is a member of the family of acyl-CoA binding pro-
teins expressed specifically in testis. Acyl-CoA binding proteins
(ACBPs, also know as ‘diazepam binding inhibitors’ or ‘DBIs’) bind
long-chain acyl-CoA esters with high affinity and act as intracellular
transporters and pool formers for acyl-CoA. They are also endoge-
nous ligands for the peripheral benzodiazepine receptor (PBR),
which is localized in the mitochondrial membrane, and is thought to
regulate the opening of the permeability transition pore complex
(PTPC), a central event in apoptosis. We have shown previously
that knock-out of t-ACBP leads to resistance to ceramide-induced
apoptosis in Chinese hamster ovary (CHO) cells. We have also
shown that transduction of recombinantly-produced t-ACBP into
CHO cells leads to apoptosis by activation of caspase 3. One possi-
ble explanation for this behaviour is that ceramide up-regulates the
interaction of t-ACBP with the PBR, leading to opening of the PTPC.
A second explanation is that knock-out of t-ACBP leads to reduction
in the availability of palmitoyl-CoA, and consequently to a lowering
of the level of endogenous ceramide, rendering the cells less sensi-
tive to exogenously introduced ceramide. We have recombinantly
expressed 13C- and 15N-enriched samples of murine t-ACBP and
used heteronuclear NMR spectroscopy to show that it binds
strongly to palmitoyl-CoA. No significant binding was observed to
either C2-ceramide or C16-ceramide. We conclude from this that if
t-ACBP does play a role in the opening of the PTPC in response to
ceramide, it does not do so by direct interaction with ceramide. We
therefore conclude that it is the interaction of t-ACBP with
palmitoyl-CoA that holds the key to its role in ceramide-induced
apoptosis. This preliminary study serves to illustrate the power of
NMR spectroscopy as a tool for probing protein–ligand and
protein–protein interactions, which has not previously been
exploited in South Africa.
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In addition to their interaction with the PBR, ACBPs have been
well described as acyl-CoA binding proteins.28 ACBPs play the
role of acyl-CoA transporters and pool-formers, maintaining a
supply of soluble acyl-CoAs for a wide range of cellular pro-
cesses.5,19,29–32 These include endogenous synthesis of ceramide
by serine palmitoyl-CoA transferase, for which palmitoyl-CoA is
a substrate.33 An alternative explanation for the effect of t-ACBP
knock-out on ceramide-induced apoptosis is that disruption of
the pool-forming activity of t-ACBP may lead to suppression of
endogenous levels of ceramide, resulting in reduced sensitivity
to exogenously introduced ceramide.
Previous structural studies have investigated the interactions
between members of the ACBP family and a range of different-
chain-length acyl-CoAs.34 The structure of bovine l-ACBP bound
to palmitoyl-CoA has been determined using heteronuclear
NMR,35 and the residues involved in the interaction identified
using 15N-HSQC spectra. The molecule has been used exten-
sively as a model system to study the folding and stability of al-
pha-helical proteins36–40 using NMR spectroscopy. The structures
of l-ACBP from bovine liver and from P. falciparum have been
determined using X-ray crystallography,41 and a number of
differences observed between the binding pockets of the two
proteins, which correlate with small changes in specificity.
Although no previous structural studies have been reported on
t-ACBP, due to the high degree of sequence similarity its struc-
ture is not expected to be significantly different from that of
l-ACBP. However, the presence of 20 highly conserved residues
specific to the t-ACBP sub-family6 suggests that there may be
significant functional differences between t-ACBPs and other
members of the ACBP family.
We have addressed two possible explanations for the effect of
the knock-out of t-ACBP on ceramide-induced apoptosis. First,
that t-ACBP interacts directly with ceramide, abolishing its inter-
action with the peripheral benzodiazapine receptor, and
thereby preventing opening of the mitochondrial transition
pore. Second, that t-ACBP plays a role in the maintenance of
intracellular levels of endogenous ceramide by supplying
palmitoyl-CoA to the biosynthetic ceramide pathway. Knock-
out of t-ACBP would therefore be expected to lead to a lowering
of endogenous ceramide levels, thereby rendering the cells less
sensitive to exogenously introduced ceramide.
Materials and methods
Sequences
The nucleotide sequence coding for t-ACBP was PCR amplified out of
genomic DNA isolated from mouse embryonic stem cell using forward
primer 5’CATGCTAGATCTATGAGCCAAGTG3’ and reverse primer
5’GAAGACCTCGAGTTAGCATGGCTC3’. Primers were designed based
on the gene sequence AF229807. The forward primer incorporated a
Bgl II site and the reverse an Xho I site for cloning into the Bam HI and Xho
I sites in the multiple cloning cassette of the pGEX-6P-2 vector.
Protein expression and purification
Transformed cells were grown at 37°C in M9 Minimal Medium (incor-
porating 15NH4Cl and supplemented with 2 g/l
13C-glucose) until the
OD260 reached 0.4–0.6, after which they were induced with 1 mM IPTG
and grown for a further 16–18 hours at 30°C. The cells were harvested
and re-suspended in GST Binding Buffer (PBS, pH 7.4, including
150 mM NaCl, 0.01% Triton, 1 mM DTT, 1 mM EDTA, 1 mM PMSF), after
which they were lysed using the freeze–thaw method (–80°C for 5 min
followed by 37°C for 5 min, repeated 3 times). Following centrifugation
(6000 × g for 30 min at 4°C) the supernatant was loaded onto a 10 ml
gravity-fed glutathione–agarose column and the column washed with
3 column volumes of binding buffer. The fusion protein was eluted with
elution buffer (50 mM Tris-HCl, pH 8, including 15 mM reduced gluta-
thione, 1 mM EDTA, 1 mM PMSF).
Eluted fusion protein was first dialysed into cleavage buffer (50 mM
Tris-HCl, pH 7.0, including 150 mM NaCl, 1 mM EDTA, 1 mM DTT,
0.01% Triton, 1 mM PMSF) and then 3C protease was added (home-
made, activity un-characterized) and cleavage allowed to take place at
4°C overnight. Cleaved GST was removed using 20 HQ anion exchange
chromatography; at pH 7 the GST (pI 5.6) was retained by the column
whereas the target protein (pI 8.8) remained behind in the flow-through.
As a final purification step, the target protein was concentrated into 1 ml
using YM-3 Centriprep devices (Millipore, Bedford, MA) and applied to
a 1 m × 0.8 cm2 Sephacryl S100 size exclusion column (Amersham Biosci-
ences), which had been equilibrated in NMR Buffer (50 mM sodium
phosphate, pH 6.0, + 10 mM DTT + 50 mM NaCl + 7% D2O). Fractions
containing t-ACBP were pooled and concentrated into 500 µl for NMR
analysis. Mass spectrometry showed a single species of the expected
molecular weight. The concentration was quantified using Bradford
Assay,45 using commercial lysozyme as a reference.
NMR
All NMR spectra were recorded on the 600-MHz Varian NMR spec-
trometer of the Central Analytical Facility at the University of
Stellenbosch. Spectra were processed using NMRPIpe46 and visualized
using NMRView.47 15N-HSQC spectra were recorded using a 5 mm indi-
rect detection PFG probe, using the ghsqc_da pulse sequence, with
8 transients per FID, 128 increments in the indirect dimension and 1024
complex points in the direct dimension.
For sequential assignment, CBCA(CO)NH and HNCACB spectra
(refs 42 and 50) were recorded using a 5 mm HCN PFG triple-resonance
probe, using pulse-sequences from the Varian BioPack software suite
(Varian, Inc., Palo Alto, CA); 8 transients per FID, 128 increments in the
carbon dimension and 64 increments in the nitrogen dimension were
used in both cases. Strip plots were generated in NMRView using a peak
list picked from an HNCO spectrum. Assignments were checked
with the help of an H(CCO)NH spectrum, which correlates side-chain
protons of residue i – 1 with the HN and N of residue i.
Binding analysis
Peak volumes were calculated using NMRView, and corrected for
changes in concentration due to changes in the volume of the NMR
sample on addition of ligand. θ was calculated using Equation (1). Bind-
ing curves were generated using proFit (QuantumSoft, Zürich, Switzer-
land; www.quansoft.com) and fitted to the theoretical expression
θ =
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where [P] is the protein concentration (fixed), [L] is the ligand concentra-
tion (the independent variable) and KD is the dissociation constant
whose value is to be determined. [P] and KD were both allowed to vary
during the fitting.
Modelling
A model of t-ACBP was generated using MODELLER48,49 (accessible
through the ESyPred3D server: www.fundp.ac.be/urbm/bioinfo/
esypred) based its primary sequence homology with l-ACBP. Graphical
representations were generated using PyMOL [DeLano W.L. (2002). The
PyMOL Molecular Graphics System. DeLano Scientific, San Carlos, CA;
www.pymol.org].
Results
To investigate the binding of various ligands to t-ACBP,
15N-enriched samples of GST-tagged t-ACBP were expressed in
bacteria by growing transformed E. coli cells on minimal media
incorporating [15N]ammonium chloride as the sole nitrogen
source. The protein was expressed as a C-terminal fusion with
the 26-kDa glutathione-S-transferase (GST) protein from S. japo-
nicum, and the GST was subsequently removed using 3C
protease followed by anion exchange chromatography.
Removal of GST left the five amino acids Gly-Pro-Leu-Gly-Ser
fused to the N-terminus of t-ACBP, resulting in a 92-residue
protein with an expected size of 10.2 kDa. After final purification
using size exclusion chromatography, the protein was concen-
trated to a final concentration of 0.5 mM for NMR analysis. A
1-dimensional proton NMR spectrum is shown in Fig. 1.
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Two-dimensional 15N-HSQC NMR spectra were used to probe
the binding of ligands to 15N-enriched t-ACBP. Each resonance in
a 15N-HSQC spectrum of a protein (with a number of exceptions,
including the NH2 doublets at the top right of the spectrum)
corresponds to the backbone NH group of a single amino acid,
with the horizontal and vertical coordinates corresponding to
the magnetic precession frequencies of the 1H and 15N nuclei,
respectively. Both frequencies are highly sensitive to the binding
of ligands in the immediate vicinity of the NH group, often due
to the making or breaking of hydrogen bonds involving the NH
group, making it a powerful probe of protein–ligand, as well as
of protein–protein, interactions.
Addition of C16-ceramide had no effect on the
15N-HSQC spec-
trum, even at fivefold excess relative to the protein concentra-
tion. Similar results were obtained using C2-ceramide. We
conclude from this that there is no significant binding of either
form of ceramide to t-ACBP. In contrast, addition of even small
amounts of palmitoyl-CoA led to a decrease in the amplitude of a
number of resonances, and the appearance of new resonances
nearby. Figure 2 shows an overlay of t-ACBP before (in black)
and after (in red) the addition of a twofold excess of palmitoyl-
CoA. A large number of the black resonances have completely
disappeared, suggesting that at twofold excess the protein is
already completely saturated. We conclude from the changes to
the spectrum that palmitoyl-CoA binds directly and strongly to
t-ACBP. Only 15N-enriched compounds were visible in
15N-HSQC spectra, which means that the ligand itself did not
appear in the spectrum. In total we identified 20 resonances
which disappeared from the spectrum on addition of ligand,
with the appearance of a similar number elsewhere; however,
until both the liganded and the un-liganded spectra have
been assigned, we are not able to match the liganded with the
un-liganded resonances. Two cases in which both the un-ligan-
ded and the corresponding liganded resonances are clearly
identifiable are indicated by boxes.
Furthermore, since the liganded and un-liganded states have
distinct resonances, we conclude that we are in the so-called
‘strong-binding limit’. In this case the
liganded and un-liganded states behave as
separate species during the NMR acquisi-
tion period, and the respective resonances
are proportional to the numbers of mole-
cules in each state. (This is in contrast to the
‘weak-binding limit’ , in which the
l iganded and un-l iganded states
inter-convert during the acquisition time,
and a single resonance is observed at the
population-weighted average of the two
resonances.)
Since we were in the strong-binding








where Vbound and Vunbound represent the vol-
umes of the respective resonances. Figure
3B shows a plot of θ as a function of ligand
concentration for residue Lys17, which is
one of the residues indicated by a box in
Fig. 2. θ increases approximately linearly
with ligand concentration and levels off
sharply at θ = 1, when the ligand concen-
tration equals the protein concentration.
This indicates that the protein sequesters all available ligand un-
til it is saturated, which corresponds to strong binding. The solid
line in Fig. 3B corresponds to the theoretical expression for θ
[Equation (1)], and gives a value for the dissociation constant KD
of 3.6 ± 6.9 µM. KD is therefore in the micromolar range, corre-
sponding to strong binding. However, as can be seen from the
error bars, the value obtained was an upper limit on KD, since
decreasing KD further would have the effect of only sharpening
the ‘turnover’ of the graph in Fig. 3B, and our data are not com-
prehensive enough to probe this area of the curve. A more signif-
icant measurement of KD would require the protein
concentration to be of the same order of magnitude as KD. This
Fig. 1. One-dimensional proton NMR spectrum of t-ACBP, recorded in 93%
H2O/7% D2O at 25°C on the 600-MHz Varian NMR spectrometer at the University of
Stellenbosch.The concentration of the sample was 1.2 mM.The residual H2O reso-
nance is at 4.7 ppm and the backbone HN resonances which form the focus of
NMR-based binding experiments are found between 7 and 11 ppm. The spectrum
is well dispersed (note in particular the peaks to the right of 0 ppm and to the left of
9 ppm), indicating that the protein is folded.
Fig. 2. Overlay of the 15N-HSQC spectrum of t-ACBP before (in black) and after (in red) addition of twofold
excess palmitoyl-CoA. In a large number of cases the black resonances have completely disappeared from the
liganded spectrum, indicating that at twofold excess the protein is already completely saturated. Two
well-resolved examples of liganded/un-liganded pairs of resonances are indicated by boxes.
would not, however, be measurable using this
method, since a micromolar protein concentra-
tion would be difficult to detect using NMR.
To establish the identities of the amino acids
corresponding to the shifting resonances, dou-
ble-labelled (13C- and 15N-enriched) samples of
t-ACBP were prepared and used to record triple-
resonance coherence transfer spectra from
which we sequentially assigned 80% of the resi-
dues (refs 42 and 50). Assignment of the protein
is ongoing and a more complete treatment of the
assignments will be published elsewhere. Based
on these assignments, we have established that
the two resonances boxed in Fig. 2 correspond to
Lys17 and Gly18, respectively.
To determine if the residues identified above
are consistent with the binding site identified in
previous studies, we used MODELLER to build
an homology model of t-ACBP based on the
structure of bovine l-ACBP. Figure 4A shows a
surface representation of the modelled structure
of t-ACBP, with Lys17 and Gly18 indicated in red.
Figure 4B shows the same view of the NMR
structure of bovine l-ACBP, with palmitoyl-CoA shown in green.
It is clear by comparison of Figs 4A and B that palmitoyl-CoA
binds into a similarly shaped binding pocket on t-ACBP and that
the residues identified by NMR are likely to be intimately
involved in the binding interaction. Perhaps interestingly, a
10-residue stretch of the protein which we have so far not been
able to assign due to low intensity of the resonances, lies directly
in the modelled binding pocket. The reason for the low intensity
is not clear, although it is possible that the sample contains
acyl-CoA-like molecules originating from the expression host
which are engaging in on–off interactions, leading to exchange-
broadening of the NMR resonances.
Discussion
We have previously shown that CHO cells in which the
murine t-ACBP protein has been knocked out are resistant to
ceramide-induced apoptosis, and that transduction of recombi-
nantly-produced protein into CHO cells results in apoptosis by
the induction of caspase 3.2 Given that t-ACBP is a member of the
acyl-CoA-binding protein family, we sought to determine
whether t-ACBP exerts its effect on apoptosis directly, by inter-
acting with ceramide, or indirectly, by acting as a transporter of
palmitoyl CoA.
We have expressed murine t-ACBP protein recombinantly in
E. coli and used heteronuclear NMR to show that it does not have
any significant interaction with either C2-ceramide or C16-cera-
mide. If t-ACBP does play a role in permeabilization of the mito-
chondrial membrane in response to ceramide, it does not do so
by direct interaction with ceramide. On the other hand, it does
interact strongly with palmitoyl-CoA, with a KD in the sub-
micromolar range.
Using double-labelled samples, we sequentially assigned the
protein using triple-resonance transfer experiments, and hence
identified a number of residues involved in the binding interac-
tion between t-ACBP and palmitoyl-CoA. These experiments
were carried out on the 600-MHz Varian NMR spectrometer at
the University of Stellenbosch, and represent the first sequential
assignment of a protein NMR spectrum in South Africa. The
binding residues identified by NMR are consistent with the
homology model of t-ACBP based on the structure of l-ACBP
bound to palmitoyl-CoA. In future work, we aim to produce
mutants by substitution of the binding residues in order to
abolish binding to palmitoyl-CoA while retaining the structural
integrity of the overall protein. These mutants will then be tested
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Fig. 4. A, Surface representation of the modelled structure of t-ACBP, showing the boxed residues from Fig. 2 in red; B, surface representation of the same orientation
of l-ACBP, showing palmitoyl-CoA bound in green.
Fig. 3. A, Close-up of the region around Lys17 showing the un-liganded resonance (bottom right) being
replaced by the liganded resonance (top left) as ligand is added; B, plot of the volume of the liganded
peak as a function of ligand concentration. The fitted curve corresponds to Equation (1).
A B
434 South African Journal of Science 101, Sept./Oct. 2005 NRF/Royal Society Programme
for their ability to induce apoptosis in order to test the hypothe-
sis that transport of palmitoyl-CoA by t-ACBP is required for
ceramide-induced apoptosis.
The preliminary results reported here illustrate the power of
heteronuclear NMR spectroscopy as a tool for investigating pro-
tein–ligand and protein–protein interactions. 15N-HSQC spectra
such as the one shown in Fig. 2 require only moderate concentra-
tions of protein (>0.1 mM in a sample volume of 0.5 ml) and
require that the samples be 15N-labelled but not 13C-labelled. For
protein–protein interactions, one of the proteins should be
15N-labelled and the other unlabelled, so that only the reso-
nances of the labelled protein appear in the 15N-HSQC spec-
trum. Experiments of this type provide a convenient method of
screening a single protein against a library of potential ligands
which is currently in widespread use in the pharmaceutical
industry.43,44 If binding is observed, residues involved in the
binding site may be identified by expressing 13C-labelled
samples and using triple-resonance experiments to assign
sequentially the resonances of the 15N-HSQC spectrum, as
described elsewhere in this issue.50
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